COMMUNIQUÉS West-GlobeNewswire

CooperCompanies Announces First Quarter 2026 Results
05/03/2026
SAN RAMON, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2026. First [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
05/03/2026
CONSHOHOCKEN, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Amneal to Participate in Upcoming Investor Conference
05/03/2026
BRIDGEWATER, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, will participate in a fireside chat at the following [...]
Calidi Biotherapeutics Announces Proposed Public Offering
05/03/2026
SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today [...]
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights
05/03/2026
GLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as early as 2H 2026 Entered strategic collaboration with GSK to advance RNA-based therapeutic [...]
Nyxoah Publiera ses Résultats Financiers du Quatrième Trimestre et de l’Année 2025 le 19 Mars 2026
05/03/2026
Nyxoah Publiera ses Résultats Financiers du Quatrième Trimestre et de l’Année 2025 le 19 Mars 2026 Mont-Saint-Guibert, Belgique – 5 mars 2026, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« [...]
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
05/03/2026
Data readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated in Q2 2026 LNCB74 Phase 1 dose escalation trial update planned in second half of [...]
Nova Leap Health Corp. Posts Fourth Quarter and Record Full-Year 2025 Revenues and Adjusted EBITDA
05/03/2026
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, March 05, 2026 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a [...]
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
05/03/2026
Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS) Oral presentation on updated KYSA-6 Phase 2 data in generalized myasthenia gravis (gMG) [...]
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
05/03/2026
ISELIN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, [...]
President & CEO Letter to Shareholders
05/03/2026
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, March 05, 2026 (GLOBE NEWSWIRE) -- Dear Nova Leap Health Corp. (“Nova Leap” or the “Company”) Shareholders: [...]
Omada Health Announces GLP-1 Flex Care, Giving Employers a New, Flexible Path to Support Obesity Care
05/03/2026
Through Omada’s GLP-1 Flex Care offering, employers gain a new flexible option to connect employees with anti-obesity medication, virtual care, and lifestyle support SAN FRANCISCO, March 05, 2026 (GLOBE NEWSWIRE) -- [...]
Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical
05/03/2026
WARREN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) [...]
MediWound Files Annual Report on Form 20-F
05/03/2026
MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5 , 202 6 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, t oday announced that it has filed [...]
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
05/03/2026
Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America [...]
COSCIENS Provides Strategic Update
05/03/2026
TORONTO, ONTARIO, March 05, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“ COSCIENS ” or the “ Company ”) today announced that the Company has made a strategic decision to cease funding [...]
Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
05/03/2026
Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 Mont-Saint-Guibert, Belgium – March 5 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “ [...]
Regeneron Announces Investor Conference Presentation
05/03/2026
TARRYTOWN, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation at the Barclays 28th Annual Global Healthcare Conference at 9:00 a.m. ET on [...]
Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development
05/03/2026
Commercially launched in the U.S. in November 2025, TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime is the first new FDA-approved treatment for fibromyalgia in adults in more than [...]

Pages